INVO BioScience Reports Q3 Results with EPS Beat and Revenue Growth
INVO BioScience reported third-quarter financial results characterized by a significant earnings per share (EPS) beat despite missing revenue expectations. The company posted a GAAP EPS of -$2.24, which exceeded analyst estimates by $18.56. While revenue grew 26.9% year-over-year to $2.22 million, this figure fell short of consensus estimates by approximately $0.49 million. The company's consolidated adjusted EBITDA was a loss of $1.0 million, a slight increase in deficit compared to the $(0.9) million reported in the prior year period. As of September 30, 2026, INVO BioScience held $3.7 million in cash, representing approximately $3.10 per share.

Topics: earnings report EPS beat financial results revenue miss